Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 11 - 02 tags : Disease save search
uniQure Announces Latest Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
Published: 2021-11-02 (Crawled : 17:00) - biospace.com/
QURE | $4.755 -1.35% -1.37% 460K
|
Health Technology
|
| O: -0.63%
H: 9.62%
C: 8.29%
huntington disease treatment test positive trial huntington’s disease
TCT 2021: Philips announces new innovations and clinical data supporting the treatment of patients with cardiovascular disease
Published: 2021-11-02 (Crawled : 15:00) - globenewswire.com
PHG | News | $21.01 1.94% 0.0% 2M
|
Health Technology
|
| O: 0.44%
H: 0.25%
C: -0.42%
disease treatment cardiovascular cardio
Annovis Bio to Present at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference
Published: 2021-11-02 (Crawled : 14:00) - biospace.com/
ANVS | $11.88 3.39% 0.0% 230K
|
Health Technology
|
| O: -0.54%
H: 12.67%
C: 11.73%
disease alzheimer clinical trials trials trial conference alzheimer’s alzheimer's disease alzheimer's
Aldeyra Therapeutics Announces Achievement of Primary Endpoint of Ocular Redness in Randomized, Double-Masked, Vehicle-Controlled Phase 2 Clinical Trial in Dry Eye Disease
Published: 2021-11-02 (Crawled : 13:00) - biospace.com/
ALDX | $3.91 -0.51% -0.51% 450K
|
Health Technology
|
| O: -0.43%
H: 0.97%
C: -4.65%
dry eye disease phase 2 eye ocular eye disease trial mask
Cyclo Therapeutics Names Preeminent Neuroscientist and World-Renowned Researcher, Cynthia A. Lemere, PhD, as Senior Advisor for Advancement of Alzheimer’s Disease Asset
Published: 2021-11-02 (Crawled : 13:00) - biospace.com/
CYTH | $1.26 7.94% 33K
|
Professional, Scientific, and T...
|
| O: 1.0%
H: 8.37%
C: 8.37%
disease alzheimer research alzheimer’s alzheimer's disease alzheimer's
Acumen Pharmaceuticals to Present Clinical Trial Design for INTERCEPT-AD, the Phase 1 Placebo-Controlled, Single- and Multiple-Dose Clinical Trial of ACU193, at 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Published: 2021-11-02 (Crawled : 12:00) - globenewswire.com
ABOS | $3.15 0.64% 0.63% 270K
|
Professional, Scientific, and T...
|
| O: -4.4%
H: 8.83%
C: -1.17%
disease alzheimer clinical trials phase 1 trials trial conference alzheimer’s alzheimer's disease alzheimer's designation
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.